Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
Entropy Neurodynamics Granted Australian Patent for TRP8803 to Treat Chronic Pain and Psychiatric Conditions
Entropy Neurodynamics (ASX: ENP) granted Australian patent for TRP8803 (IV psilocybin) for chronic pain and neuropsychiatric disorders; protection to 2042.
Latest Stories
Paradigm Biopharmaceuticals Publishes Canine Osteoarthritis Study Showing Durable PPS Benefits
Paradigm Biopharmaceuticals (ASX: PAR) reports durable 26-week canine OA PPS benefits in peer-reviewed PLOS One, bolstering translational human OA potential.
TruScreen Validated as Superior Cervical Cancer Screening Tool in Major Chinese Study
TruScreen Group (ASX: TRU) announced strong validation results from a major Chinese study for its cervical cancer screening tool, positioning it for guidelin
Rhythm Biosciences begins ColoSTAT commercial deployment with first physician enrollment
Rhythm Biosciences (ASX: RHY) has initiated the commercial deployment of its ColoSTAT test by enrolling the first physician in its capped Access Program.
EVE Health Group Launches Libbo ED Treatment and Men’s Health Platform
EVE Health (ASX: EVE) launches Libbo ED treatment and men’s health platform, unveiling an end-to-end digital pathway for nationwide access and scalable revenue.
Memphasys Prepares for First Australian Sales after Felix Sperm Separation Device Gains TGA Approval
Memphasys (ASX: MEM) gains TGA approval for Felix device, enabling immediate Australian sales and clinic deployments two months ahead of schedule.
Algorae Pharmaceuticals Partners with Cadila to Market Two New Medicines in Australia and NZ
Algorae inks Cadila deal to market two cardio/metabolic generics in Australia & NZ; Cadila develops/manufactures; AlgoraeRx handles regulatory and marketing.
Immutep TACTI-004 NSCLC Trial At 50% Enrolment, Paving Way for Futility Analysis
Immutep (ASX: IMM) has achieved a significant milestone, announcing 50% patient enrolment in its global Phase III TACTI-004 trial for first-line non-small ce
Island Pharmaceuticals Raises $9m to Fund Clinical Development as FDA Approves Galidesivir Pathway
Island Pharmaceuticals (ASX: ILA) secures FDA Animal Rule path for galidesivir and $9m funding to fast-track two-stage trials and US govt procurement potential.
Rhythm Biosciences Secures Key Manufacturing Deal for ColoSTAT
Rhythm Biosciences (ASX:RHY) has secured a multi-year manufacturing agreement with Quansys Biosciences for its ColoSTAT reagent kits, ensuring scalab
Neurotech International Secures HREC Approval for Pivotal Phase 3 ASD Study of NTI164
Neurotech International (ASX: NTI) has secured Human Research Ethics Committee (HREC) approval to commence its pivotal Phase 3 clinical study for **NTI16
Algorae Pharmaceuticals Advances Commercial Pathway as AI Platform Validation and Distribution Agreements Gather Pace
Algorae Pharmaceuticals (ASX: 1AI) advances AlgoraeOS validation and signs Dr Reddy's distribution, signals near-term oncology revenue and stronger balance sheet.